Sinovac Biotech Ltd.’s vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot, which performed far worse than western vaccines in clinical trials.
Indonesia tracked 128,290 health workers in capital city Jakarta from January to March and found that the vaccine protected 98% of them from death and 96% from hospitalization as soon as seven days after the second dose, Pandji Dhewantara, a Health Ministry official who oversaw the study, said in a Wednesday press conference.
Dhewantara also said that 94% of the workers had been protected against symptomatic infection -- an extraordinary result that goes beyond what was measured in the shot’s numerous clinical trials. Health Minister Budi Gunadi Sadikin earlier revealed a smaller version of the study involving 25,374 people in a Tuesday interview with Bloomberg that had the same effectiveness data for hospitalization and infection. Protection against death was 100% in the smaller group.
Sinovac Biotech Ltd.’s vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot, which performed far worse than western vaccines in clinical trials.
Indonesia tracked 128,290 health workers in capital city Jakarta from January to March and found that the vaccine protected 98% of them from death and 96% from hospitalization as soon as seven days after the second dose, Pandji Dhewantara, a Health Ministry official who oversaw the study, said in a Wednesday press conference.
Dhewantara also said that 94% of the workers had been protected against symptomatic infection -- an extraordinary result that goes beyond what was measured in the shot’s numerous clinical trials. Health Minister Budi Gunadi Sadikin earlier revealed a smaller version of the study involving 25,374 people in a Tuesday interview with Bloomberg that had the same effectiveness data for hospitalization and infection. Protection against death was 100% in the smaller group.
A spokesman for Sinovac in Beijing said the company cannot comment on the Indonesian study until it acquires more details.
The Indonesian study compared vaccinated against non-vaccinated people to derive the estimated effectiveness. The median age of the participants is 31 years old.
In a separate interview with Bloomberg Tuesday, Sinovac’s chief executive officer Yin Weidong defended the disparity in clinical data around the shot, and said there was growing evidence CoronaVac is performing better when applied in the real world.
Read More on website: https://www.bloomberg.com/news/articles/2021-05-11/china-s-sinovac-shot-found-highly-effective-in-real-world-study?srnd=premium-asia&utm_source=url_link
Comments